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Abstract
Evidence indicates that synchronization of cortical activity at gamma-band frequencies, mediated through GABA-A
receptors, is important for perceptual/cognitive processes. To study GABA signaling in vivo, we recently used a novel
positron emission tomography (PET) paradigm measuring the change in binding of the benzodiazepine (BDZ) site
radiotracer [
11C]flumazenil associated with increases in extracellular GABA induced via GABA membrane transporter (GAT1)
blockade with tiagabine. GAT1 blockade resulted in significant increases in [
11C]flumazenil binding potential (BPND) over
baseline in the major functional domains of the cortex, consistent with preclinical studies showing that increased GABA
levels enhance the affinity of GABA-A receptors for BDZ ligands. In the current study we sought to replicate our previous
results and to further validate this approach by demonstrating that the magnitude of increase in [
11C]flumazenil binding
observed with PET is directly correlated with tiagabine dose. [
11C]flumazenil distribution volume (VT) was measured in 18
healthy volunteers before and after GAT1 blockade with tiagabine. Two dose groups were studied (n=9 per group; Group I:
tiagabine 0.15 mg/kg; Group II: tiagabine 0.25 mg/kg). GAT1 blockade resulted in increases in mean (6 SD) [
11C]flumazenil
VT in Group II in association cortices (6.860.8 mL g21 vs. 7.360.4 mL g21;p=0.03), sensory cortices (6.760.8 mL g21 vs.
7.360.5 mL g21;p=0.02) and limbic regions (5.260.6 mL g21 vs. 5.760.3 mL g21;p=0.03). No change was observed at
the low dose (Group I). Increased orbital frontal cortex binding of [
11C]flumazenil in Group II correlated with the ability to
entrain cortical networks (r=0.67, p=0.05) measured via EEG during a cognitive control task. These data provide a
replication of our previous study demonstrating the ability to measure in vivo, with PET, acute shifts in extracellular GABA.
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Accumulating evidence indicates that synchronization of cortical
neuronal activity at gamma-band frequencies (30–80 Hz), mediated
through GABA-A receptor transmission, is important for various
types of perceptual [1,2,3] and cognitive processes [4,5]. In order to
assess the relationship between changes in gamma band power and
extracellular GABA levels, we recently using a novel positron
emission tomography (PET) brain-imaging paradigm to measure
the in vivo binding of the benzodiazepine (BDZ) site specific
radiotracer [
11C]flumazenil [6] at baseline and in the context of
elevated GABA levels induced via blockade of the GABA
membrane transporter (GAT1) with tiagabine (GabitrilH) [7].
Preclinical work suggests that increased GABA levels enhance the
affinity of GABA-A receptors for BDZ ligands via a conformational
change (termed the ‘GABA-shift’) [8,9,10]; such an increase in
affinity of GABA-A receptors should be detected as an increase in
the binding of a GABA-A BDZ-receptor site-specific PET
radioligand. In our study, GAT1 blockade resulted in significant
increases in [
11C]flumazenil binding potential (BPND) over baseline
in brain regions representing the major functional domains of the
cerebral cortex and this increase strongly predicted (r=0.85,
p=0.015) the ability to entrain cortical networks, measured via
EEG gamma synchrony during a cognitive control task in these
same subjects [7]. These findings are consistent with the results of
experimental models[11,12]as well as preclinical studies [13,14,15]
suggesting that GABA-A receptor-mediated transmission is re-
quired for the induction of gamma network oscillations.
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32443The aim of the current study was to replicate our previous
results and to further validate the methods by demonstrating that
the magnitude of increase in [
11C]flumazenil binding observed
with PET is directly correlated with the degree of GABA increase.
The refinement and validation of the PET methodology described
previously would provide a unique ability to measure changes in
extracellular GABA levels in vivo; examine the relationship
between GABA neurotransmission, oscillatory activity and cogni-
tion; and to explore differences between control and patient
populations in the degree of extracellular GABA increase in
response to a standardized level of GAT1 blockade. Moreover, if
abnormalities in GABA transmission exist in psychiatric disorders
as suggested by recent studies in schizophrenia [16] and major
depression [17], this technique could be employed in the process of
developing new pharmacologic compounds with the target of
increasing cortical GABA levels. Eighteen healthy volunteers
underwent two [
11C]flumazenil PET scans on the same day,
baseline and 60 minutes after administration of oral tiagabine;
nine subjects received a dose of 0.15 mg/kg and nine subjects
received a dose of 0.25 mg/kg. We hypothesized that the increase
in [
11C]flumazenil binding after the administration of tiagabine
will occur in a dose-dependent manner.
Materials and Methods
Human Subjects
The study was approved by the Institutional Review Board of
the University of Pittsburgh Medical Center. Eighteen healthy
volunteers provided written, informed, consent and participated in
this study in two dose groups (Group I: tiagabine 0.15 mg/kg, age
2463 years, range 21 to 29, 4M/5F; Group II: tiagabine
0.25 mg/kg, age 30611 years, range 19 to 48, 5M/4F; with
these and subsequent values given as mean 6 SD). The absence of
pregnancy, medical, neurological and psychiatric history (includ-
ing alcohol and drug abuse) was assessed by history, review of
systems, physical examination, routine blood tests including
pregnancy test, urine toxicology and EKG. Subjects provided
written informed consent after receiving an explanation of the
study.
PET protocol
All subjects were studied twice with [
11C]flumazenil on the
same day. On the study day an arterial catheter was inserted in the
radial artery, after completion of the Allen test and infiltration of
the skin with lidocaine, for blood sampling and a venous catheter
was inserted in a forearm vein for radiotracer injection. First, a
baseline PET scan was performed. The baseline scan was followed
by oral administration of tiagabine (Group I 0.15 mg/kg; Group
II 0.25 mg/kg) with the second PET scan beginning 60 minutes
post-tiagabine administration. Calculated tiagabine dose was
rounded to the nearest even number to prevent tablet splitting
(lowest dosage form is a 2 mg tablet).
The scanning protocol was identical for all scans. PET imaging
was performed with the ECAT EXACT HR+ (Siemens/CTI,
Knoxville, TN). A 10 min transmission scan was obtained prior to
each radiotracer injection for attenuation correction of the
emission data. [
11C]Flumazenil was produced via a modification
of published procedures [18]. Twenty mCi or less of high specific
activity [
11C]flumazenil was injected i.v. over 30 sec. Emission
data were collected in the 3D mode for 90 min as 19 successive
frames of increasing duration (4615 s, 361 min, 362 min,
265 min, 7610 min). Subjects were allowed to rest outside of
the camera for 30–60 min between the two injections. Subjects
remained in the Montefiore University Hospital Clinical and
Translational Research Center overnight after the PET scans to
monitor for any side effects of tiagabine administration. Adverse
effects observed in this study included sedation (mild to moderate)
and ataxia (mild) and resolved completely within 4 hours of the
scan.
Input function measurement
Following radiotracer injection, arterial samples were collected
manually approximately every 6 s for the first two min and
thereafter at longer intervals. A total of 35 samples were obtained
per scan. Following centrifugation (2 min at 12,500 rpm, Spec-
trafuge 16M), plasma was collected in 200 mL aliquots and
activities were counted in a gamma counter (Packard Biosciences).
To determine the plasma activity representing unmetabolized
parent compound, seven samples (collected at 2, 5, 15, 30, 45, 75
and 90 min) were further processed via aqueous/organic extrac-
tion [19] to measure the fractional concentrations of hydrophilic
metabolites and unchanged (lipophilic) [
11C]flumazenil. The seven
measured, unmetabolized fractions were fitted to the sum of one
exponential plus a constant and this function was used to
interpolate values between the measurements.
The input function was calculated as the product of total counts
and interpolated unmetabolized fraction at each time point. The
measured input function values were fitted to a sum of three
exponentials from the time of peak plasma activity and the fitted
values were used as the input to the kinetic analysis. The clearance
of the parent compound (L/h) was calculated as the ratio of the
injected dose to the area under the curve of the input function
[20].
For the determination of the plasma free fraction (fP), triplicate
aliquots of plasma collected prior to injection were mixed with the
radiotracer, pipetted into ultrafiltration units (Amicon Centrifree;
Bedford, MA) and centrifuged at room temperature (30 min at
6000 rpm). At end of centrifugation, the plasma and ultrafiltrate
activities were counted (Packard Biosciences), and fP was
calculated as the ratio of activity in the ultrafiltrate to total
activity [21]. Triplicate aliquots of saline solution mixed with the
radiotracer were also processed, to determine the filter retention of
the free tracer.
MRI acquisition and segmentation procedures
To provide an anatomical framework for analysis of the PET
data, MRI scans were obtained using a 1.5 T GE Medical Systems
(Milwaukee, WI) Signa Scanner. A 3D spoiled gradient recalled
sequence was acquired in the coronal plane using parameters that
were optimized for maximal contrast among gray matter, white
matter, and CSF. The scalp and calvarium were removed from the
SPGR MR images, to facilitate MR/PET coregistration, using a
manual in-house stripping technique. MRI segmentation was
performed using the FAST automated segmentation tool [22]
implemented in the FMRIB Software Library, v4.0 [23].
Image analysis
PET data were reconstructed using filtered back-projection
(Fourier rebinning/2D backprojection, 3 mm Hann filter) and
corrected for photon attenuation (
68Ge/
68Ga rods), scatter [24],
and radioactive decay. Reconstructed image files were then
processed with the image analysis software MEDx (Sensor
Systems, Inc., Sterling, Virginia) with the PET-MR image
alignment performed using the SPM2 package (www.fil.ion.ucl.
ac.uk/spm). PET data were inspected for subject motion and
inter-frame motion was corrected using the realign procedure
within SPM2, if necessary.
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MRI according to criteria derived from brain atlases [25,26] and
applied to the coregistered dynamic PET data to generate regional
time-activity curves. Three functionally-based cortical ROIs were
obtained as weighted averages of component ROIs: Association
Cortex (dorsolateral prefrontal, orbital frontal, medial prefrontal,
anterior cingulate), Sensory Cortex (parietal, occipital), and the
limbic Medial Temporal Lobe (MTL; amygdala, hippocampus,
enterorrhinal ctx and parahippocampal gyrus).
For the neocortical regions, ‘‘large’’ regions were first drawn to
delineate the boundaries of the ROIs. Within these regions, only the
voxels classified as gray matter were used to measure the activity
distribution. Sampled volumes of the neocortical regions (n=6) were as
follows: dorsolateral prefrontal cortex (DLPFC, 1939062899 mm
3),
orbito-frontal cortex (OFC, 1026062448 mm
3), medial prefrontal
cortex (MPFC, 500161660 mm
3), anterior cingulate cortex (ACC,
25876686 mm
3), parietal cortex (PC, 74583613081 mm
3), and
occipital cortex (OC, 4928667651 mm
3).
Because of the mixture of gray and white matter in the
structures of the MTL, the segmentation-based approach was not
used for the component ROIs, and the boundaries of these regions
were identified by anatomical criteria. These regions (n=4)
included amygdala (AMY, 24106404 mm
3), hippocampus (HIP,
47296877 mm
3), entorhinal cortex (ENT 9606243 mm
3), and
parahippocampal gyrus (PHG, 602161382 mm
3).
For bilateral regions, right and left values were averaged. The
contribution of plasma total activity to the regional activity was
calculated assuming a 5% blood volume in the regions of interest
[27] and tissue activities were calculated as the total regional
activities minus the plasma contribution.
Derivation of distribution volumes
We denote here the outcome variables using the consensus
nomenclature for in vivo imaging of reversibly binding radioli-
gands [28]. Derivation of [
11C]flumazenil regional tissue distribu-
tion volume (VT,m Lg
21) was performed with kinetic modeling
using the arterial input function and an unconstrained two tissue
compartment model (2TC model). VT, which is equal to the ratio
of tissue to plasma parent activity at equilibrium, was derived as
K1/k2(1+k3/k4), where K1 (ml g
21 min
21) and k2 (min
21) are the
unidirectional fractional rate constants governing the transfer into
and out of the brain, respectively, and k3 (min
21) and k4 (min
21)
are the unidirectional fractional rate constants governing the
association and dissociation of [
11C]flumazenil to and from the
BZD-site, respectively [29,30,31]. Kinetic parameters were
derived by nonlinear regression using a Levenberg-Marquart
least-squares minimization procedure [32] implemented in
MATLAB (The Math Works, Inc., South Natick, MA), as
previously described [30]. Given the unequal sampling over time
(increasing frame acquisition time from the beginning to the end of
the study), the least-squares minimization procedure was weighted
by the frame acquisition time.
In previous studies, including our own [7], the pons has been
used as the region of reference as activity in this region has been
reported to represent predominantly nonspecific binding
[21,31,33]. However, postmortem studies [34,35,36] as well as
previous receptor imaging studies [20], including unpublished
imaging data from our lab in humans, have demonstrated
significant (up to 60%) of the signal from the pons is due to
specific binding. While in our previous study tiagabine adminis-
tration did not alter the pons VT (equilibrium nonspecific binding,
VND) since the current study compared two dose of tiagabine we
elected to utilize the VT as our main outcome measure. However,
for the purpose of comparison, we include the [
11C]flumazenil
binding potential relative to the total plasma concentration of
[
11C]flumazenil (BPP,m Lg
21) derived as the difference between
VT in the ROI and VND (pons VT). The relationship between BPP
and BDZ receptor parameters is given by BPP=fP*Bmax/KD,
where Bmax is GABA-A BDZ-receptor density, 1/KD is the in vivo
affinity of [
11C]flumazenil for the GABA-A BDZ-receptor and fP is
the fraction of the radiotracer unbound to protein in the plasma.
Derivation of Affinity Shift via Linear Regression Analysis
Lassen et al [37] demonstrated the ability to estimate the
fractional change in binding potential (DBP) as the slope of the
linear regression of the difference in VT across conditions vs. the
baseline VT for cases where only the distribution volume and not
the binding potential can be measured. In this study the linear
regression of (VT baseline - VT post tiagabine) vs. VT baseline results in a
line with a slope of DBP and an x-intercept of VND. Assuming the
affinity shift secondary to increased GABA levels is the same across
all regions the shift in affinity is equal to 1- DBP, or 1 – slope of the
plot of (VT baseline - VT post tiagabine) vs. VT baseline. In each subject the
percent change in affinity as well as VND was determined via this
method using the values of VT from the ten ROIs examined in the
study (DLPFC, OFC, MPFC, ACC, PC, OC, AMY, HIP, ENT,
and PHG) pre- and post-tiagabine administration.
Electrophysiology and Cognitive Task
In all subjects the electrophysiology study was performed
approximately 1 week prior to the PET scans. The Preparing to
Overcome Prepotency (POP) task is a cued stimulus-response
reversal paradigm that requires increases in cognitive control to
overcome prepotent response tendencies [38]. Trials proceeded in
the following order: cue (a green or red square; 500 ms); delay
period (1000 ms); probe (a white arrow pointing left or right;
1000 ms); and a variable inter-trial interval (1000–2000 ms). Cues
indicated conditions requiring either low (green square) or high
(red square) degrees of cognitive control. Over the delay period,
subjects were required to maintain the trial-type information and
prepare for a response to the upcoming probe. For low-control
trials, subjects were required to respond in the direction of the
arrow that followed (e.g., for a right-pointing arrow, press the right
button); for the high-control trials, responses were required in the
opposite direction (e.g., for a right-pointing arrow, press the left
button). To reinforce the prepotency of the cue-probe mappings of
the low-control trials, thereby increasing the control requirements
during the high-control trials, 70% of the trials were low-control
and the remaining 30% were high-control. Trial types were
interleaved in pseudorandom order, with 8 blocks of 42 trials each.
During the POP task, EEG data were acquired using a 129 Ag-
AgCl coated carbon fiber electrode Geodesic Sensor Net (EGI,
Eugene, OR) with a sampling frequency of 250 Hz. Data were
filtered on-line with a 0.1–100 Hz band pass hardware filter.
Electrode impedances were kept below 50 kV. All channels were
referenced to Cz. Epochs were defined as 2400 to +1900 ms
relative to the cue onset. Error trials and epochs containing
artifacts were excluded (20 channels with amplitude range
exceeding 200 mV within a segment and/or having 60 mV
deviations between consecutive samples). Segments identified by
these criteria were visually inspected prior to rejection. Blink and
ECG artifacts were removed with ICA based detection and
correction methods. Data were filtered off-line using an 1–100 Hz
finite impulse response filter. The resulting data were submitted to
final review using the above amplitude and gradient criteria and
for 60 Hz line noise, with bad channel data being replaced by
interpolation. Data were re-referenced to average reference [39].
GABA Effect on [
11C]flumazenil Binding
PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e32443Average segment counts for the high and low control conditions
were 220 and 80, respectively.
Time-frequency analyses were carried out using Brain Vision
Analyzer (Brain Products GmbH, Munich, Germany). The data
were transformed using complex Morlet wavelet transforms,
defined by mo(x)=c?exp(2x
2/2)?exp(iv0x), with c=7, using 20
frequency steps spanning 14–80 Hz. Wavelet transformed data
were baseline corrected to a 2300 to 2100 ms pre-cue interval.
EEG analysis involved identifying frontal areas of peak induced
(i.e., not time locked to stimulus) gamma activity differences
between the high and low control conditions, with a focus on the
delay period (500–1500 ms relative to cue onset) during which
induced frontal gamma activity has been shown to modulate in
accordance with cognitive control demands [38]. Activity from
one representative electrode from each of the left and right frontal
areas, respectively, was averaged to derive a spatially averaged
measure for comparison to the PET data. The peak activity was in
the gamma sub-band with central frequency 42 Hz in a left frontal
region consisting of adjacent electrode locations E23, E24 and E27
(approximately AF3 and AF7, respectively, in the 10-10 system).
This procedure resulted in one summary measure of frontal
gamma activity for each subject, which were then compared to the
individual measurements of tiagabine induced increase in
[
11C]flumazenil binding by PET. Note that an experimenter
blind to the PET data performed the determinations of these EEG
measures of frontal gamma.
Statistical analysis
Between scan comparisons were assessed with a paired, two-
tailed t-test with a significance level of 0.05. Baseline and post-
tiagabine K1 and VT for the three functional cortical regions and
VND (pons VT) were compared using a two-tailed, paired t-test,
with an uncorrected probability value of 0.05 selected as the
significance level. For the analysis of the tiagabine-induced change
in VT in the component ROIs (n=10) a univariate repeated-
measures analysis of variance (RM ANOVA) with brain regions as
the within-scan factor and condition (baseline or post-tiagabine) as
the between-scan factor was used. Paired t-tests were performed,
when appropriate, to determine which regions accounted for
significant effects observed in the RM ANOVA. The relationship
between the PET scan outcome measures and the measurement of
gamma-band power were analyzed with the Pearson product
moment correlation coefficient after first confirming normal
distribution of the data using the Kolmogorov-Smirnov test.
Results
PET scan parameters
No difference was observed in the injected dose, specific activity
or injected mass of [
11C]flumazenil between the baseline and post-
tiagabine scan in either group (Table 1). Tiagabine administration
did not affect the plasma clearance of [
11C]flumazenil, [
11C]flu-
mazenil plasma free fraction (fP) or the distribution volume (VT)o f
[
11C]flumazenil in the pons (Table 1).
Regional distribution volumes, K1 values and BZD
receptor availability
Dose Group I: Administration of 0.15 mg/kg tiagabine did
not result in a significant change in VT in any of the large cortical
regions (these and subsequent values noted as mean 6 standard
deviation, p values for two-tailed, paired t-test unless otherwise
stated); Association Cortex 7.660.6 mL g
21 vs. 7.760.4 mL g
21
(p=0.84), Sensory Cortex 7.560.5 mL g
21 vs. 7.361.0 mL g
21
(p=0.64) and limbic Medial Temporal Lobe (MTL)
5.960.5 mL g
21 vs. 5.960.3 mL g
21 (p=0.86). Examination of
VT across the component ROIs revealed significant regional effect
(RM ANOVA F=186.3, df=9, 8, p,0.0001), no region by
condition interaction (RM ANOVA F=0.51, df=9, 8, p=0.84)
and no significant difference across conditions (RM ANOVA
F=0.008, df=1, 16, p=0.93), see Table 2.
Similarly, neither K1 (Table 3) nor BPP (Table 4) were changed
with the 0.15 mg/kg dose of tiagabine. Examination of K1
revealed a significant regional effect (RM ANOVA F=265.4,
df=9, 8, p,0.0001), no region by condition interaction (RM
ANOVA F=0.47, df=9, 8, p=0.86) and no difference across
conditions (RM ANOVA F=1.3, df=1, 16, p=0.27). Examina-
Table 1. Demographic and scan data.
Dose Group I Dose Group II
Parameter Baseline Post-tiagabine p Baseline Post-tiagabine p
N 99- 9 9-
Age 23.762.5 - - 30.6610.9 - -
Gender 4M/5F - - 5M/4F - -
Ethnicity 1AA/7C/1H - - 3AA/6C - -
Tiagabine
Dose (mg/kg) - 0.1460.01 - - 0.2460.01 -
Plasma level
1 (ng/mL) - 141655 - - 291669 -
Injected dose (mCi) 19.962.0 20.461.8 0.45 20.960.8 21.061.0 0.72
SA (Ci/mmoles) 19636757 20076693 0.89 183761048 225462068 0.55
Injected Mass (ug) 3.460.9 3.561.6 0.79 4.663.0 4.763.9 0.86
Free Fraction (fP, %) 58.0%67.6% 59.6%66.1% 0.31 54.6%67.8% 56.9%65.2% 0.12
Clearance (L/h) 53667 53623 1.00 43622 56625 0.23
Pons VT (or VND mL/g) 1.060.1 1.060.1 0.56 0.960.1 1.060.1 0.17
AA, African-American, AS, Asian, C, Caucasian. Significance level given is for a paired, two-tailed t-test.
1Plasma level take at the time of the scan.
doi:10.1371/journal.pone.0032443.t001
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F=186.4, df=9, 8, p,0.0001), no region by condition interaction
(RM ANOVA F=0.51, df=9, 8, p=0.84) and no difference
across conditions (RM ANOVA F=0.05, df=1, 16, p=0.83).
Dose Group II: After the administration of 0.25 mg/kg
tiagabine VT increased significantly in the large cortical regions;
Association Cortex 6.860.8 mL g
21 vs. 7.360.4 mL g
21 (p=0.03),
Sensory Cortex 6.760.8 mL g
21 vs. 7.360.5 mL g
21 (p=0.02) and
limbic Medial Temporal Lobe (MTL) 5.260.6 mL g
21 vs.
5.760.3 mL g
21 (p=0.03). Examination of VT across the compo-
nent ROIs revealed a significant regional effect (RM ANOVA
F=118.9, df=9, 8, p,0.0001), no region by condition interaction
(RM ANOVA F=0.42, df=9, 8, p=0.42) and a trend-level
difference across conditions (RM ANOVA F=4.0, df=1, 16,
p=0.06). On a region-by-region basis, significant increases in all
regions were seen post-tiagabine (Table 2) with the exception of the
orbital prefrontal cortex (ORB, p=0.11), anterior cingulate cortex
( A C C ,p=0 . 0 8 )a n dt h ea m y g d a l a( A M Y ,p=0 . 1 1 ) .N os i g n i f i c a n t
correlations between age or tiagabine plasma concentration and VT
increase were noted.
As observed in the lower dose group K1 (Table 3) did not change
significantly with the administration of 0.25 mg/kg of tiagabine; a
significant regional effect (RM ANOVA F=249.7, df=9, 8,
p,0.0001), no region by condition interaction (RM ANOVA
F=0.57, df=9, 8, p=0.82) and no difference across conditions
(RM ANOVA F=0.66, df=1, 16, p=0.43) were observed.
However, as opposed to the lower dose level, BPP increased
significantly in the large cortical regions with 0.25 mg/kg of
tiagabine (Table 4); Association Cortex 5.960.7 mL g
21 vs.
6.460.4 mL g
21 (p=0.05), Sensory Cortex 5.860.7 mL g
21 vs.
6.360.5 mL g
21 (p=0.03) and limbic Medial Temporal Lobe
(MTL) 4.360.6 mL g
21 vs. 4.760.3 mL g
21 (p=0.04). Exami-
nation of BPP across the component ROIs revealed a significant
regional effect (RM ANOVA F=118.9, df=9, 8, p,0.0001), no
region by condition interaction (RM ANOVA F=0.42, df=9, 8,
p=0.89) and a trend-level difference across conditions (RM
ANOVA F=3.31, df=1, 16, p=0.09).
Linear Regression Analysis
In Dose Group I, given the lack of change in VT, the linear
regression analysis did not result in meaningful data. In Dose
Group II the average slope was 20.2762.84 and the average x-
intercept was 1.5367.14 (n=9 subjects). The affinity shift,
calculated as 1 – slope, was 1.2762.84, in other terms, on
average, a 27% increase in affinity was observed across subjects in
this dose group.
Electroencephalogram (EEG) induced gamma-band
oscillations
To confirm our previous results which indicated that individuals
with greater capacity to increase extracellular GABA levels post-
tiagabine (a ‘‘GABA reserve’’) would exhibit enhanced frontal
gamma-band oscillatory activity in the context of a task that taps
cognitive control processes [7], all subjects underwent EEG
measurement of frontal lobe gamma-band oscillations during the
Preparing to Overcome Prepotency (POP) task [38]. Frontal
cortical gamma-band power was measured in each individual
during the delay period. Given that no change in [
11C]flumazenil
binding was noted in Dose Group I, it would not be expected to
note an association between change in [
11C]flumazenil binding
and gamma band power; in fact this was confirmed (r=0.12,
p=0.76). For Group II the association between gamma-band
power and the ability to increase extracellular GABA levels was
significant in the orbital frontal cortex (r=0.67, p=0.05; Figure 1)
but in none of the other regions examined, although the
directionality was the same across all regions. No relationship
was observed between behavioral performance on the POP task
and gamma-band power or change in [
11C]flumazenil binding as
all individuals performed at a high level on the task.
Discussion
The results of this study confirm our previous finding that acute
increases in extracellular cortical GABA can be detected as an
increase in binding of the BDZ-site specific radiotracer, [
11C]flu-
Table 2. Tiagabine-induced change in [11C]flumazenil VT in control subjects.















Association Cortex 7.6±0.6 7.7±0.4 0.8±6.5 20.07 0.84 6.8±0.8 7.3±0.4 9.3±11.4 20.99 0.03
-DLPFC 7.660.6 7.660.4 0.566.0 20.03 0.92 6.760.8 7.260.4 9.5611.2 21.00 0.03
-Orbital Frt Ctx 7.560.7 7.560.6 0.467.8 20.01 0.98 6.760.7 7.260.5 8.0613.0 20.82 0.11
-MPFC 8.060.6 8.160.5 1.067.0 20.11 0.77 7.161.0 7.860.5 11.2612.3 20.92 0.02
-Ant. Cingulate Ctx 7.860.6 8.060.5 2.967.9 20.38 0.36 7.260.8 7.760.5 7.5611.3 20.72 0.08
Sensory Cortex 7.5±0.5 7.3±1.0 21.9±14.9 0.26 0.64 6.7±0.8 7.3±0.5 9.7±10.8 20.97 0.02
-Parietal Ctx 7.360.4 7.460.4 0.868.1 20.08 0.87 6.660.8 7.160.5 9.5611.3 20.88 0.03
-Occipital Ctx 7.760.6 7.461.5 24.2621.2 0.34 0.53 7.060.8 7.660.4 9.7610.2 21.06 0.02
Medial Temporal Lobe 5.9±0.5 5.9±0.3 0.0±7.8 0.07 0.86 5.2±0.6 5.7±0.3 9.4±10.7 21.02 0.03
-Amygdala 5.960.6 5.860.4 20.6610.1 0.14 0.73 5.260.6 5.660.4 8.0612.0 20.79 0.11
-Hippocampus 6.060.5 5.960.3 21.168.3 0.23 0.58 5.160.5 5.660.4 10.1610.6 21.15 0.02
-Entor. Ctx 5.660.4 5.660.3 0.967.9 20.09 0.84 5.160.7 5.560.3 9.7611.6 20.83 0.03
-Parahippocampus 6.060.5 6.060.3 0.667.2 20.03 0.93 5.460.7 5.860.3 9.4610.6 20.89 0.02
Values are Mean 6 SD, in healthy controls (n=9 per group); p is the significance level of the difference between the baseline and post-tiagabine scans in each group
(paired t-test); d is the Cohen’s effect size of this difference.
doi:10.1371/journal.pone.0032443.t002
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ship in the magnitude of the increase in [
11C]flumazenil binding
and provide an estimate of the change in affinity at the BZD-site
(27% increase) resulting in the increased binding. A critical
assumption of this study is that systemic administration of
tiagabine results in an acute, dose-dependent, increase in
extracellular GABA. Tiagabine is a highly selective GAT1 blocker,
without significant affinity for other receptors which, in humans,
exhibits linear pharmacokinetics over the dose range of 2–24 mg
with high oral bioavailability (90%) and peak plasma levels at
approximately 1 hr post-dose [40]. In humans, tiagabine dose has
been correlated to changes in brain GABA levels by the
observation that there is a significant relationship between dose
and reduction in seizure frequency [41] and through a
microdialysis study in a single patient which found a 50% increase
in hippocampal GABA levels with a 16 mg oral dose, occurring
1 hr post-dose and sustained for several hours [42]. Rodent
microdialysis studies have shown that ip injection of tiagabine
(11.5 and 21 mg/kg) increases extracellular GABA concentration
,200%–400% over basal levels in a dose-dependent manner,
Table 3. Tiagabine-induced change in [11C]flumazenil K1 in control subjects.
Dose Group I (0.15 mg/kg) Dose Group II (0.25 mg/kg)
Subdivision
- Component ROIs Baseline K1 Post-tiagabine K1 d p Baseline K1 Post-tiagabine K1 dp
Association Cortex 0.441±0.03 0.463±0.04 20.66 0.18 0.405±0.06 0.421±0.05 20.31 0.27
-DLPFC 0.44760.03 0.46760.04 20.57 0.22 0.40760.06 0.42460.05 20.34 0.21
-Orbital Frt Ctx 0.42960.03 0.45260.04 20.67 0.23 0.39460.06 0.41160.05 20.36 0.22
-MPFC 0.45260.04 0.47760.04 20.72 0.15 0.41960.07 0.43860.05 20.32 0.14
-Ant. Cingulate Ctx 0.42560.04 0.45560.04 20.77 0.08 0.40860.06 0.43460.06 20.45 0.09
Sensory Cortex 0.438±0.04 0.447±0.07 20.17 0.73 0.412±0.05 0.425±0.05 20.28 0.21
-Parietal Ctx 0.44360.04 0.46860.04 20.66 0.18 0.41260.05 0.43260.05 20.40 0.08
-Occipital Ctx 0.42960.05 0.42860.10 0.02 0.96 0.40860.05 0.41960.04 20.25 0.28
Medial Temporal Lobe 0.308±0.03 0.332±0.04 20.68 0.10 0.291±0.04 0.304±0.03 20.40 0.17
-Amygdala 0.31660.04 0.33160.03 20.42 0.33 0.29560.04 0.29860.03 20.09 0.75
-Hippocampus 0.31060.03 0.33260.04 20.67 0.06 0.28760.03 0.30960.02 20.78 0.03
-Entor. Ctx 0.27060.04 0.29460.03 20.72 0.07 0.26460.04 0.28060.03 20.50 0.16
-Parahippocampus 0.30860.03 0.33160.04 20.63 0.10 0.29360.04 0.31160.03 20.52 0.06
Values are Mean 6 SD, in healthy controls (n=9 per group); p is the significance level of the difference between the baseline and post-tiagabine scans in each group
(paired t-test); d is the Cohen’s effect size of this difference.
doi:10.1371/journal.pone.0032443.t003
Table 4. Tiagabine-induced change in [11C]flumazenil BPP in control subjects.

















Association Cortex 6.6±0.6 6.7±0.4 0.5±7.0 20.02 0.95 5.9±0.7 6.4±0.4 9.5±12.7 20.91 0.05
-DLPFC 6.660.6 6.660.4 0.266.2 0.02 0.94 5.860.7 6.360.4 9.7612.6 20.91 0.05
-Orbital Frt Ctx 6.560.6 6.560.6 0.168.6 0.04 0.91 5.860.7 6.260.5 8.0614.9 20.70 0.17
-MPFC 7.060.5 7.160.5 0.767.6 20.06 0.87 6.260.9 6.860.5 11.6613.1 20.87 0.03
-Ant. Cingulate Ctx 6.860.6 7.060.4 3.068.8 20.34 0.41 6.360.8 6.760.6 7.4612.8 20.62 0.14
Sensory Cortex 6.5±0.5 6.3±0.9 22.5±17.1 0.30 0.60 5.8±0.7 6.3±0.5 10.0±11.8 20.90 0.03
-Parietal Ctx 6.360.4 6.460.4 0.569.3 20.02 0.97 5.760.7 6.260.5 9.7612.5 20.81 0.04
-Occipital Ctx 6.760.6 6.361.5 25.0624.2 0.37 0.50 6.160.7 6.660.4 9.9610.9 20.99 0.02
Medial Temporal Lobe 4.9±0.5 4.9±0.3 20.5±8.2 0.14 0.71 4.3±0.6 4.7±0.3 9.7±11.6 20.91 0.04
-Amygdala 4.960.6 4.860.5 21.3610.5 0.19 0.61 4.460.5 4.660.3 8.0613.0 20.69 0.15
-Hippocampus 5.060.5 4.960.4 21.868.7 0.28 0.43 4.260.5 4.660.3 10.6611.2 21.04 0.02
-Entor. Ctx 4.660.4 4.660.3 0.568.8 20.01 0.98 4.260.7 4.660.3 10.3613.5 20.69 0.06
-Parahippocampus 5.060.5 5.060.4 0.367.9 0.03 0.93 4.560.6 4.860.3 9.7611.7 20.78 0.03
Values are Mean 6 SD, in healthy controls (n=9 per group); p is the significance level of the difference between the baseline and post-tiagabine scans in each group
(paired t-test); d is the Cohen’s effect size of this difference.
doi:10.1371/journal.pone.0032443.t004
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administration of tiagabine (1 mg/kg iv), a 2-fold increase in
extracellular GABA levels was observed, reaching a maximum
approximately 70 minutes post-tiagabine in vervet monkeys [45].
Taken together these preclinical studies support the assumption
that extracellular GABA levels increase in a dose-dependent
manner with tiagabine.
The principle underlying the hypothesis of a ‘GABA-shift’ is the
enhancement in BDZ-receptor affinity for BDZ-site substrates
resulting from increased GABA [9,10]. It is widely accepted that
BDZs potentiate the effects of GABA at the GABA-A receptor and
the reverse is true, increased GABA levels potentiate the binding of
BDZs to the GABA-A receptor in a dose-dependent manner [9].
Some in vitro studies exploring this phenomenon indicate that it is
specific to agonist drugs [46] while other in vitro studies were not
able to demonstrate the GABA-shift, even with BDZ agonists [47].
Two preclinical studies have examined the effects of increasing
GABA and GABAergic drugs on flumazenil binding in intact
animals and both found results consistent with our findings. The
first [48] demonstrated enhanced [
3H]flumazenil binding in vivo
when mice were treated with either progabide (a GABA analog
and agonist at the GABA-A receptor) or valproate, which increases
brain GABA levels [49]. The second [8] measured the effects of
three GABAergic drugs, aminooxyacetic acid (inhibitor of GABA
transaminase, the enzyme that metabolizes GABA), gamma-vinyl
GABA (GVG, irreversible GABA transaminase inhibitor) and
valproate on [
3H]flumazenil binding. All three drugs resulted in
acute increases in cortical GABA concentrations and specific
binding of [
3H]flumazenil increased acutely across all brain
regions, with all three drugs, with no change in nonspecific
binding. These results, as well as those observed in our studies,
suggest that while flumazenil acts as a benzodiazepine site
antagonist in most settings it may also behave as a high affinity
partial agonist with weak efficacy in others. This hypothesis is
consistent with studies showing flumazenil to be anxiolytic in some
rodent models of anxiety [50] as well as in normals in stressful
(public speaking) settings but not at baseline [51], to reduced
benzodiazepine withdrawal symptoms in dependent subjects [52]
and to enhance the GABA-A receptor mediated currents evoked
by GABA [53].
The strengths of the present study include measurement of the
arterial input function, allowing for the assessment of the effects of
tiagabine on VND and fP. While the absence of change in these
variables post-tiagabine validates the use of either BPP or BPND as
an outcome measure, we chose to use VT, derived via 2TC
modeling, as our primary outcome measure. Our rationale for
selecting VT as the outcome measure in this study was the
postmortem studies [34,35,36], previous receptor imaging study
[20] and unpublished data from our lab, all of which demonstrate
a significant degree of specific binding in the pons (up to 60%). We
were concerned that differential effects of elevated GABA levels on
[
11C]flumazenil specific binding in the pons would impact the
comparison across tiagabine dose groups. Since we anticipated a
greater increase in [
11C]flumazenil binding in the high dose group,
specific binding within the pons would impact either BPP or BPND
to a greater degree in this group relative to the low dose group
potentially obscuring group differences in tiagabine induced
change in [
11C]flumazenil binding, despite the fact that, on
average, no changes were seen in the pons VT post tiagabine in
either group. In fact, this is what we observed; as pons VT is
progressively included in the outcome measure there is a loss of
significant differences likely secondary to elevations in pons VT
with tiagabine administration. Examination of VT (Table 2), BPP
(Table 4) and BPND (data not shown) in the high dose group
demonstrates a significant change in VT, a trend-level change in
BPP, and no change in BPND.
In our previously published study we noted a relatively high
variability in the percent change in [
11C]flumazenil binding across
subjects. One factor we postulated may be involved in the
variability was the timing of the PET scan relative to the
administration of tiagabine [6]. In our initial study, we timed the
PET scan such that scanning commenced at 30 min post dose to
ensure the measurement occurred during the acute increase in
GABA coinciding with the reported Tmax of the plasma
concentration of tiagabine (45–60 min); however, microdialysis
studies indicate GABA increases are sustained for several hours
after oral administration of tiagabine. In the current study we
increased the time between tiagabine administration and the start
of PET scanning from 30 to 60 min, allowing for more consistent
absorption of tiagabine across subjects. In addition we based the
tiagabine dose on subject weight as opposed to using a standard,
single, dose for each subject (as we did in our first study). Despite
these changes in study design the variability in the percent change
in [
11C]flumazenil binding was not significantly altered nor did we
detect a correlation between tiagabine plasma level and change in
[
11C]flumazenil binding (data not shown). In our first study we
noted a significant increase in VT across the ROIs used in this
study (average increase in VT of 13.7%615.9%). This increase is
comparable, albeit numerically larger, to that observed in Dose
Group II, where we noted an average increase in VT of
9.3%610.9% across the 10 component ROIs listed in Table 2.
Detecting differences between individuals with a psychiatric
disorder and healthy controls may be challenging with this level
of variability in the measurement; however, comparing the two
groups in this study we noted the increase in [
11C]flumazenil VT to
be greater for Group II vs. Group I at a trend level (p=0.06, RM
ANOVA). In other words, relatively large between-dose differ-
ences can be detected with the current method (the average
Figure 1. The ability to increase GABA levels in the orbito-
frontal cortex, measured as the change in [
11C]flumazenil
binding in response to GAT1 blockade, predicts (r=0.67,
p=0.05) the ability to entrain cortical networks, measured
via EEG gamma oscillations.
doi:10.1371/journal.pone.0032443.g001
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subtle differences in GABA availability may be difficult to detect
without improvements in the methods to reduce the variability.
The goal of the present study was to validate our previous
findings by demonstrating that the magnitude of increase in
[
11C]flumazenil binding observed with PET is directly correlated
with the degree of increase in extracellular GABA. We utilized
increased tiagabine dose as a proxy for increased extracellular
GABA levels since the only direct method to examine this
hypothesis would be combined PET/microdialysis studies in
nonhuman primates, which are confounded by the necessary
anesthesia. Our results provide additional evidence supporting the
idea that the GABA-shift phenomenon can be observed in vivo,
using PET, in humans. The ability to measure in vivo changes in
extracellular GABA levels provides a unique opportunity to
explore the role of GABA in certain brain processes. Studies with
nonhuman primates demonstrate that the disruption of GABA
transmission in the DLFPC impairs working memory [54]. In
humans, DLPFC gamma oscillations normally increase with
working memory load [55], a phenomena which is impaired in
subjects with working memory deficits [38]. In addition to playing
a role in working memory [5], gamma synchrony appears to be
associated with other higher cognitive processes such as associative
learning [4]. Although the specific role of GABA transmission in
working memory is still under investigation, the synchronization of
pyramidal cell firing by networks of fast-spiking, parvalbumin-
containing GABA neurons gives rise to oscillatory activity in the
gamma range [56]. While not powered to examine this issue
specifically, in the current study, as in our previous one, we
observed a relationship between the change in [
11C]flumazenil
binding (in dose Group II) and the ability to entrain oscillatory
activity in the gamma frequency during a cognitive control task.
While in this study we only observed this relationship with one
ROI, this provides further direct support for the hypothesis that
GABA neurotransmission is linked to the synchronization of
cortical neuronal activity in humans. Continued refinement and
validation of the PET methodology described in this study is
necessary for it to consistently provide the ability to measure
changes in GABA levels in vivo; however, it provides a unique
method to explore differences between control and patient
populations in the degree of extracellular GABA increase in
response to a standardized level of GAT1 blockade.
Acknowledgments
We are grateful to the research subjects who participated in this study. The
authors thank members of the PET Facility Staff who carried out the
acquisition of PET data and care of all subjects during PET procedures.
Author Contributions
Conceived and designed the experiments: WGF RYC DAL CAM RN.
Performed the experiments: NSM CW. Analyzed the data: CMC MH.
Wrote the paper: WGF RN.
References
1. Lutzenberger W, Pulvermuller F, Elbert T, Birbaumer N (1995) Visual
stimulation alters local 40-Hz responses in humans: an EEG-study. Neuroscience
Letters 183: 39–42.
2. Sanes J, Donoghue J (1993) Oscillations in Local Field Potentials of the Primate
Motor Cortex During Voluntary Movement. PNAS 90: 4470–4474.
3. Tiitinen H, Sinkkonen J, Reinikainen K, Alho K, et al. (1993) Selective attention
enhances the auditory 40-Hz transient response in humans. Nature
Vol 364(6432, Jul 1993, 59–60 Nature Publishing Group, United Kingdom.
4. Miltner WHR, Braun C, Arnold M, Witte H, Taub E (1999) Coherence of
gamma-band EEG activity as a basis for associative learning. Nature 397:
434–436.
5. Howard MW, Rizzuto DS, Caplan JB, Madsen JR, Lisman J, et al. (2003)
Gamma Oscillations Correlate with Working Memory Load in Humans.
Cerebral Cortex 13: 1369–1374.
6. Persson A, Ehrin E, Eriksson L, Farde L, Hedstrom CG, et al. (1985) Imaging of
[11C]-labelled Ro 15-1788 binding to benzodiazepine receptors in the human
brain by positron emission tomography. J Psychiatr Res 19: 609–622.
7. Frankle WG, Cho RY, Narendran R, Mason NS, Vora S, et al. (2009)
Tiagabine increases [11C]flumazenil binding in cortical brain regions in healthy
control subjects. Neuropsychopharmacology 34: 624–633.
8. Miller LG, Greenblatt DJ, Barnhill JG, Summer WR, Shader RI (1988) ‘GABA
shift’ in vivo: enhancement of benzodiazepine binding in vivo by modulation of
endogenous GABA. Eur J Pharmacol 148: 123–130.
9. Tallman JF, Thomas JW, Gallager DW (1978) GABAergic modulation of
benzodiazepine binding site sensitivity. Nature 274: 383–385.
10. Braestrup C, Schmiechen R, Neef G, Nielsen M, Petersen EN (1982) Interaction
of convulsive ligands with benzodiazepine receptors. Science 216: 1241–1243.
11. Bartos M, Vida I, Jonas P (2007) Synaptic mechanisms of synchronized gamma
oscillations in inhibitory interneuron networks. Nat Rev Neurosci 8: 45–56.
12. Van Vreeswijk C, Abbott LF, Ermentrout GB (1994) When inhibition not
excitation synchronizes neural firing. J Comput Neurosci 1: 313–321.
13. Mann EO, Suckling JM, Hajos N, Greenfield SA, Paulsen O (2005) Perisomatic
feedback inhibition underlies cholinergically induced fast network oscillations in
the rat hippocampus in vitro. Neuron 45: 105–117.
14. Hajos N, Palhalmi J, Mann EO, Nemeth B, Paulsen O, et al. (2004) Spike timing
of distinct types of GABAergic interneuron during hippocampal gamma
oscillations in vitro. J Neurosci 24: 9127–9137.
15. Fuchs EC, Zivkovic AR, Cunningham MO, Middleton S, Lebeau FE, et al.
(2007) Recruitment of parvalbumin-positive interneurons determines hippo-
campal function and associated behavior. Neuron 53: 591–604.
16. Yoon JH, Maddock RJ, Rokem A, Silver MA, Minzenberg MJ, et al. (2010)
GABA concentration is reduced in visual cortex in schizophrenia and correlates
with orientation-specific surround suppression. The Journal of neuroscience : the
official journal of the Society for Neuroscience 30: 3777–3781.
17. Price RB, Shungu DC, Mao X, Nestadt P, Kelly C, et al. (2009) Amino acid
neurotransmitters assessed by proton magnetic resonance spectroscopy:
relationship to treatment resistance in major depressive disorder. Biological
Psychiatry 65: 792–800.
18. Halldin C, Stone-Enlander S, Thorell J-L, Persson A, Sedvall G (1988) 11C
Labeling of Ro 15-1788 in two different positions, and also 11C labeling of its
main metabolite Ro 15-3890, for PET studies of benzodiazepine receptors. Appl
Radiat Isot 39: 993–997.
19. Barre L, Debruyne D, Abadie P, Moulin M, Baron JC (1991) A comparison of
methods for separation of [11C]Ro 15-1788 (flumazenil) from its metabolites in
the blood of rabbits, baboons, and humans. Appl Radiat Isot 42: 435–439.
20. Abi-Dargham A, Laruelle M, Seibyl J, Rattner Z, Baldwin RM, et al. (1994)
SPECT measurement of benzodiazepine receptors in human brain with [123-
I]iomazenil: kinetic and equilibrium paradigms. J Nucl Med 35: 228–238.
21. Price JC, Mayberg HS, Dannals RF, Wilson AA, Ravert HT, et al. (1993)
Measurement of benzodiazepine receptor number and affinity in humans using
tracer kinetic modeling, positron emission tomography, and [
11C]-flumazenil.
J Cereb Blood Flow Metab 13: 656–667.
22. Zhang Y, Brady M, Smith S (2001) Segmentation of brain MR images through a
hidden Markov random field model and the expectation-maximization
algorithm. IEEE Trans Med Imaging 20: 45–57.
23. Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, et al.
(2004) Advances in functional and structural MR image analysis and
implementation as FSL. Neuroimage 23 Suppl 1: S208–219.
24. Watson C (2000) New, faster, image-based scatter correction for 3D PET. IEEE
Trans Nucl Sci 47: 1587–1594.
25. Duvernoy H (1991) The human brain. Surface, three-dimensional sectional
anatomy and MRI. New York: Sringer-Verlag Wien.
26. Talairach J, Tournoux P (1988) Co-planar stereotactic atlas of the human brain.
Three-dimensional proportional system: an approach of cerebral imaging. New
York: Theime Medical Publisher.
27. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ (1984) A
quantitative model for the in vivo assessment of drug binding sites with positron
emission tomography. Ann Neurol 15: 217–227.
28. Innis R, Cunningham VJ, Delforge J, Fujioka K, Gjedde A, et al. (2007)
Consensus nomenclature for in vivo imaging of reversibly binding radioligands.
Journal of Cerebral Blood Flow and Metabolism 2007.
29. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, et al. (2007)
Consensus nomenclature for in vivo imaging of reversibly binding radioligands.
J Cereb Blood Flow Metab 27: 1533–1539.
30. Laruelle M, Baldwin RM, Rattner Z, Al-Tikriti MS, Zea-Ponce Y, et al. (1994)
SPECT quantification of [123I]iomazenil binding to benzodiazepine receptors
in nonhuman primates. I. Kinetic modeling of single bolus experiments. J Cereb
Blood Flow Metab 14: 439–452.
GABA Effect on [
11C]flumazenil Binding
PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e3244331. Koeppe RA, Holthoff VA, Frey KA, Kilbourn MR, Kuhl DE (1991)
Compartmental analysis of [
11C]flumazenil kinetics for the estimation of ligand
transport rate and receptor distribution using positron emission tomography.
J Cereb Blood Flow Metab 11: 735–744.
32. Levenberg K (1944) A method for the solution of certain problems in least
squares. Quart Appl Math 2: 164–168.
33. Abadie P, Baron JC, Bisserbe JC, Boulenger JP, Rioux P, et al. (1992) Central
benzodiazepine receptors in human brain: estimation of regional Bmax and KD
values with positron emission tomography. Eur J Pharmacol 213: 107–115.
34. Mo ¨hler H, Okada T (1977) Benzodiazepine receptors: demonstration in the
central nervous system. Science 198.
35. Braestrup C, Albrechten R, Squires RF (1977) High densities of benzodiazepine
receptors in human cortical areas. Nature 269: 702–704.
36. Zezula J, Cortes R, Probst A, Palacios JM (1988) Benzodiazepine receptor sites
in the human brain: autoradiographic mapping. Neuroscience 25: 771–795.
37. Lassen NA, Bartenstein PA, Lammertsma AA, Prevett MC, Turton DR, et al.
(1995) Benzodiazepine receptor quantification in vivo in humans using
[11C]flumazenil and PET: application of the steady-state principle. Journal of
Cerebral Blood Flow & Metabolism 15: 152–165.
38. Cho RY, Konecky RO, Carter CS (2006) Impairments in frontal cortical
gamma synchrony and cognitive control in schizophrenia. PNAS 103:
19878–19883.
39. Bertrand O, Perrin F, Pernier J (1985) A theoretical justification of the average
reference in topographic evoked potential studies. Electroencephalogr Clin
Neurophysiol 62: 462–464.
40. Adkins JC, Noble S (1998) Tiagabine. A review of its pharmacodynamic and
pharmacokinetic properties and therapeutic potential in the management of
epilepsy. Drugs 55: 437–460.
41. Uthman BM, Rowan AJ, Ahmann PA, Leppik IE, Schachter SC, et al. (1998)
Tiagabine for complex partial seizures: a randomized, add-on, dose-response
trial. Arch Neurol 55: 56–62.
42. During M, Mattson R, Scheyer R, Rask C, Pierce M, et al. The Effect of
Tiagabine HCI on Extracellular GABA Levels in the Human Hippocampus.
Annual Meeting of the American Epilepsy Society, 1992; Seattle, Washington.
43. Richards DA, Bowery NG (1996) Comparative effects of the GABA uptake
inhibitors, tiagabine and NNC-711, on extracellular GABA levels in the rat
ventrolateral thalamus. Neurochem Res 21: 135–140.
44. Fink-Jensen A, Suzdak PD, Swedberg MD, Judge ME, Hansen L, et al. (1992)
The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases
extracellular brain levels of GABA in awake rats. Eur J Pharmacol 220:
197–201.
45. Sybirska E, Seibyl JP, Bremner JD, Baldwin RM, al-Tikriti MS, et al. (1993)
[123I]iomazenil SPECT imaging demonstrates significant benzodiazepine
receptor reserve in human and nonhuman primate brain. Neuropharmacology
32: 671–680.
46. Mohler H, Richards JG (1981) Agonist and antagonist benzodiazepine receptor
interaction in vitro. Nature 294: 763–765.
47. Rosenberg HC, Chiu TH (1979) Benzodiazepine binding after in vivo elevation
of GABA. Neurosci Lett 15: 277–281.
48. Koe BK, Kondratas E, Russo LL (1987) [
3H]Ro 15-1788 binding to
benzodiazepine receptors in mouse brain in vivo: marked enhancement by
GABA agonists and other CNS drugs. European Journal of Pharmacology 142:
373–384.
49. Johannessen CU (2000) Mechanisms of action of valproate: a commentatory.
Neurochem Int 37: 103–110.
50. Belzung C, Le Guisquet AM, Crestani F (2000) Flumazenil induces
benzodiazepine partial agonist-like effects in BALB/c but not C57BL/6 mice.
Psychopharmacology 148: 24–32.
51. Kapczinski F, Curran HV, Gray J, Lader M (1994) Flumazenil has an anxiolytic
effect in simulated stress. Psychopharmacology 114: 187–189.
52. Gerra G, Zaimovic A, Giusti F, Moi G, Brewer C (2002) Intravenous flumazenil
versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a
randomized, placebo-controlled study. Addiction biology 7: 385–395.
53. Weiss M, Tikhonov D, Buldakova S (2002) Effect of flumazenil on GABAA
receptors in isolated rat hippocampal neurons. Neurochemical research 27:
1605–1612.
54. Rao SG, Williams GV, Goldman-Rakic PS (2000) Destruction and creation of
spatial tuning by disinhibition: GABA(A) blockade of prefrontal cortical neurons
engaged by working memory. J Neurosci 20: 485–494.
55. Howard MW, Rizzuto DS, Caplan JB, Madsen JR, Lisman J, et al. (2003)
Gamma oscillations correlate with working memory load in humans. Cereb
Cortex 13: 1369–1374.
56. Sohal VS, Zhang F, Yizhar O, Deisseroth K (2009) Parvalbumin neurons and
gamma rhythms enhance cortical circuit performance. Nature 459: 698–702.
GABA Effect on [
11C]flumazenil Binding
PLoS ONE | www.plosone.org 9 February 2012 | Volume 7 | Issue 2 | e32443